Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
MBLAC2 CRISPR/Cas9 KO Plasmid (h): sc-406416
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MBLAC2 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the MBLAC2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MBLAC2 Antibody (E-7): sc-398153
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MBLAC2 CRISPR/Cas9 KO Plasmid (h) | sc-406416 | 20 µg | $397.00 |
Overview
MBLAC2 encodes a metallo-β-lactamase domain–containing protein implicated in metal-dependent hydrolytic reactions and cellular detoxification processes. Its predicted enzymatic activity suggests a role in regulating small-molecule metabolism and maintaining cellular homeostasis under oxidative or xenobiotic stress conditions. Altered expression of metallo-β-lactamase family members has been reported across multiple disease contexts, supporting investigation of MBLAC2 in pathways linked to stress responses, metabolic rewiring, and cell survival. Functional studies of MBLAC2 can inform how metallohydrolase-associated processes intersect with mitochondrial and cytosolic metabolic networks in human cells.
MBLAC2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MBLAC2 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MBLAC2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MBLAC2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish MBLAC2 protein expression.
This CRISPR knockout system enables efficient generation of MBLAC2-deficient cell models for investigation of MBLAC2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MBLAC2 exon(s) critical for MBLAC2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MBLAC2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by MBLAC2 CRISPR/Cas9 KO Plasmid (h) and MBLAC2 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MBLAC2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by MBLAC2 HDR Plasmid (h) and MBLAC2 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MBLAC2 homology arms to support homology-directed repair at defined MBLAC2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.